Compare Gilead Sciences, Inc. (GILD) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vipshop Holdings Ltd - ADR — how do they compare? Gilead Sciences, Inc. trades at $133.3 (market cap $163.51B), while Vipshop Holdings Ltd - ADR trades at $14.7 (market cap $6.83B). The key difference: Gilead Sciences, Inc. is far larger — about 23.9× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.36%). Which is the better fit depends on your goals.
| GILD | VIPS | |
|---|---|---|
Market Cap | $163.51B | $6.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $20.68 |
52-Week Low | $108.22 | $12.92 |
Enterprise Value | $178.05B | $3.43B |
Dividend Yield | 2.49% | 4.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Vipshop (VIPS) trades at $14.67, up 5.84% today, with a bullish technical signal from moving averages and oscillators. The stock shows strong profitability with a net margin of 7.07% and attractive valuation ratios, including a P/E of 6.49. Recent Q1 2026 earnings matched expectations, and the company is pursuing growth through an outlet store REIT spin-off strategy. Revenue has stabilized around $106 billion after a slight decline from 2023 peaks.
The outlook remains positive given low valuations and analyst consensus, but risks include competitive pressures in Chinese e-commerce and macroeconomic headwinds. Cash flow volatility and recent earnings misses warrant monitoring for sustained execution. The stock presents a value opportunity if growth initiatives gain traction amid industry challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
